Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Risa Kagan

Showing results (21-30 of 46) with videos related to

Pageof 5
Sort By:
Expert Opinion on Drug Safety|July 1, 2017
Safety and benefit considerations for menopausal hormone therapyJames H Pickar, David F Archer, Risa Kagan, et al.
Menopause (New York, N.Y.)|August 31, 2016
Knowledge of clinical trials regarding hormone therapy and likelihood of prescribing hormone therapyHugh S Taylor, Risa Kagan, Corrado J Altomare, et al.
The Journal of Clinical Endocrinology and Metabolism|January 16, 2014
Current and evolving approaches to individualizing estrogen receptor-based therapy for menopausal womenRichard J Santen, Risa Kagan, Corrado J Altomare, et al.
Menopause (New York, N.Y.)|July 20, 2016
Timing and persistence of effect of conjugated estrogens/bazedoxifene in postmenopausal womenRisa Kagan, Barry S Komm, Kelly A Ryan, et al.
Menopause (New York, N.Y.)|April 19, 2017
Visual improvements in vaginal mucosa correlate with symptoms of VVA: data from a double-blind, placebo-controlled trialJames A Simon, David F Archer, Risa Kagan, et al.
Menopause (New York, N.Y.)|November 28, 2023
Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopauseAntonia Morga, Mayank Ajmera, Emily Gao, et al.
Advances in Therapy|December 31, 2024
Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 StudiesRisa Kagan, Antonio Cano, Rossella E Nappi, et al.
Menopause (New York, N.Y.)|April 23, 2024
Oral lasofoxifene's effects on moderate to severe vaginal atrophy in postmenopausal women: two phase 3, randomized, controlled trialsRisa Kagan, James A Simon, Steven R Goldstein, et al.
Advances in Therapy|June 4, 2025
Response to: Letter to the Editor Regarding: Safety of Fezolinetant for Treatment of Moderate-to-Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 StudiesRisa Kagan, Antonio Cano, Rossella E Nappi, et al.
Menopause (New York, N.Y.)|December 6, 2018
Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptomsGinger D Constantine, Dennis A Revicki, Risa Kagan, et al.
Pageof 5

Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
Expert Opinion on Drug Safety|July 1, 2017
Safety and benefit considerations for menopausal hormone therapyJames H Pickar, David F Archer, Risa Kagan, et al.
Menopause (New York, N.Y.)|August 31, 2016
Knowledge of clinical trials regarding hormone therapy and likelihood of prescribing hormone therapyHugh S Taylor, Risa Kagan, Corrado J Altomare, et al.
The Journal of Clinical Endocrinology and Metabolism|January 16, 2014
Current and evolving approaches to individualizing estrogen receptor-based therapy for menopausal womenRichard J Santen, Risa Kagan, Corrado J Altomare, et al.
Menopause (New York, N.Y.)|July 20, 2016
Timing and persistence of effect of conjugated estrogens/bazedoxifene in postmenopausal womenRisa Kagan, Barry S Komm, Kelly A Ryan, et al.
Menopause (New York, N.Y.)|April 19, 2017
Visual improvements in vaginal mucosa correlate with symptoms of VVA: data from a double-blind, placebo-controlled trialJames A Simon, David F Archer, Risa Kagan, et al.
Menopause (New York, N.Y.)|November 28, 2023
Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopauseAntonia Morga, Mayank Ajmera, Emily Gao, et al.
Advances in Therapy|December 31, 2024
Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 StudiesRisa Kagan, Antonio Cano, Rossella E Nappi, et al.
Menopause (New York, N.Y.)|April 23, 2024
Oral lasofoxifene's effects on moderate to severe vaginal atrophy in postmenopausal women: two phase 3, randomized, controlled trialsRisa Kagan, James A Simon, Steven R Goldstein, et al.
Advances in Therapy|June 4, 2025
Response to: Letter to the Editor Regarding: Safety of Fezolinetant for Treatment of Moderate-to-Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 StudiesRisa Kagan, Antonio Cano, Rossella E Nappi, et al.
Menopause (New York, N.Y.)|December 6, 2018
Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptomsGinger D Constantine, Dennis A Revicki, Risa Kagan, et al.
Pageof 5